Drug
Vsf 173
Vsf 173: highest development phase Phase 2, developed by Vanda Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| VSF-173 NCT00467441 | Phase 2 | Excessive Somnolence |
Latest
No recent events.
Follow Vsf 173 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.